Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib versus imatinib in newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia
2007-003780-50Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Bosutinib with Imatinib (2 arms). Primary endpoint: Complete cytogenetic response at 1 year. Started Jan 2008; status: completed.
02
Drugs
bosutinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2007-003780-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003780-50.